Stockreport

Travere Therapeutics Announces Full FDA Approval of FILSPARI® (sparsentan), the First and Only Approved Medicine for FSGS [Yahoo! Finance]

Travere Therapeutics, Inc.  (TVTX) 
PDF Additional indication for FILSPARI expands total addressable population to more than 100,000 patients in the U.S, including more than 30,000 patients with FSGS Label [Read more]